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Abstract
Medical research that involves human subjects presents what appears to be an intractable ethical problem:
patients are exposed to risks in order to create valuable knowledge. A central goal of research is to produce
knowledge that is "important," "fruitful," or that will have "value." Indeed, federal regulations require that
research risks be reasonable in proportion to potential benefits, and in proportion to the importance of the
knowledge to be gained (45 CFR 46.111(a)(z)). Moreover, one reason that subjects participate inresearch is
to produce knowledge that will benefit others.
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ANNOTATIONS 
Medical research that involves human subjects presents what appears to 
be an intractable ethical problem: 
patients are exposed to risks in 
order to create valuable knowl-
edge. A central goal of research is 
to produce knowledge that is 
"imp~rtant,"~"fr~itful,"~or that 
will have "value."3 Indeed, federal 
regulations require that research 
risks be reasonable in proportion 
to potential benefits, and in pro-
portion to the importance of the 
knowledge to be gained (45 CFR 
46.111(a)(z)).Moreover, one rea-
son that subjects participate in 
research is to produce knowledge 
that will benefit others.4 
Unfortunately, the concept of 
value in research has received little 
attention, particularly as it relates 
to the ethics of research. While 
value has been described convinc-
ingly as central to ethical research,s 
it is less than clear how value 
should be measured. Nor has there 
been substantive discussion about 
how assessment of value should 
contribute to the ethical review of 
research. 
This lack of discussion is puz-
zling because other ethical require-
ments of research have received 
considerable attention and have 
been extensively specified. For 
instance, the U. S. Common Rule 
explicitly mandates consideration 
of a study's risks relative to its 
potential benefits, f d e r  describ-
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ing risks as being minimal, a minor 
increase over minimal risk, or 
greater than minimal risk (45 CFR 
46). Moreove~;these regulations 
are clear about the need for 
informed consent (45 CFR 46.116) 
and for written documentation of 
such consent (45 CFR 46.117), and 
subjects are said to be capable of 
consent, assent, or neither. 
Although these categories may not 
be universally endorsed, they 
nonetheless have provided a useful 
structure for protecting human 
subjects. 
There has recently been heated 
debate about how to think about 
"acceptable" risk in studies that 
offer little (if any) prospect of ben-
efit.6-8As a result, IRBs are increas-
ingly pressured to assess the value 
of a study-that is, the importdince 
of the knowledge to be gained 
from i t -as  part of their ethical 
review. In its final report, the 
National Bioethics Advisory 
Commission urged that IRBs 
assess, for each component of a 
proposed study, the balance 
between the risks it poses to sub-
jects and the knowledge it is likely 
to yield.9 This "risk-knowledge" 
standard offers IRBs guidance in 
implementing the Common Rule 
requirement that research risks be 
reasonable with respect to poten-
tial benefits and value. 
If investigatorsand IRBs are to 
consider value as rigorously as they 
do risks and potential benefits, 
they require additional conceptual 
tools. Specifically, they need a tax-
onomy of value whose categories 
promote an open and informed dis- 
cussion like the deliberations now 
undertaken about risks and poten- 
tial benefits. In this paper, we sug- 
gest such a taxonomy. 
We propose that IRBs should bal- 
ance a study's risks, potential bene- 
fits (if any), and value by consider- 
ing two kinds of value: immediate 
health value and future health value. 
We propose further that IRBs 
should decide whether a study offers 
either of these kinds of value to 
future patients, to the population 
from which the subjects are selected, 
and/or to the subjects themselves. 
We contend that the resulting cate- 
gories provide a common frame- 
work for assessing value in clinical 
research. In some cases, when risk 
and value must be balanced, these 
categories can help IRBs and investi- 
gators to do so. We conclude by 
describing ways in which these cate- 
gories can help IRBs and investiga- 
tors to address some of the most 
pressing problems raised by human 
subjects research. 
Assessing Value 
A11 studies must use techniques of design and data analysis that 
peer reviewers can agree are appro- 
priate and adequate to produce 
knowledge that is generalizable. 
Indeed, generalizability is the cor- 
nerstone of the Common Rule defi- 
nition of research: "a systematic 
investigation, including research 
development, testing and evaluation, 
designed to develop or contribute to 
generalizable knowledge" (45 CFR 
46.102(d)). These requirements col- 
lectively describe a study's validity.l0 
Validity is a threshold requirement 
for all research, because it is unethi- 
cal to expose human subjects to 
risks in studies that cannot ade- 
quately answer the research ques- 
tion." At a minimum, thus, investi- 
gators and IRBs must consider a 
study's validity. 
Above this threshold of validity, 
studies also offer value. But IRBs 
may find it difficult to assess value 
for several reasons. First, there are 
numerous dimensions on which they 
might base their assessment. For 
example, IRBs might assess value 
based on characteristics of the dis- 
ease or problem under study, such 
as its prevalence, or the loss of life 
or decrease in function that it caus- 
es. Or they might assess a study's 
value based on public perceptions of 
the importance of the disease or 
problem, or according to whether 
the study's results are likely to 
enhance quality of life, decrease 
morbidity, or decrease mortality. All 
of these offer plausible guides for 
assessing value, and the choice 
among them is not clear. 
Second, IRBs face the challenge 
of measuring a study's value. Even if 
IRBs could agree on a single dimen- 
sion of value, the examples above 
suggest that value is a continuous 
variable. It will be difficult for IRBs 
to balance a study's risks against its 
value without categories of value 
that are analogous to categories of 
risks. 
Third, value may not be distrib- 
uted uniformly-that is, a study 
may offer value to some groups but 
not to others, raising concerns of 
justice and appropriate selection of 
subjects. As the Belmont Report 
notes, research should not focus on 
"persons from groups unlikely to be 
among the beneficiaries of subse- 
quent applications of the 
research."" This requirement is also 
codified in the federal regulations 
governing research that involves 
children (45 CFR 46. 306(a)) and 
prisoners (45 CFR 46.406(c)). 
These challenges suggest that any 
taxonomy of research value should 
have three properties, it should: 
clearly identify and define a single 
dimension of value; divide that 
dimension into clear categories of 
value, analogous to the categories of 
research risks and benefits; and be 
sensitive to fairness of distribution 
among potential beneficiaries. 
DefiningValue 
Following Emanuel and colleagues we define value as a study's 
potential to improve health and 
well-being.'3 This definition enjoys 
wide support and is codified in the 
Nuremberg code as the necessity of 
producing "fruitful results for the 
good of society."'4 Similarly, the 
Declaration of Helsinki proposes 
that a fundamental goal of all bio- 
medical research is "to help suffer- 
ing humanity. " ' 5  
Given the range of research that 
involves human subjects, any defini- 
tion of value must necessarily be as 
broad as possible, while at the same 
time retaining enough specificity to 
be meaningful. Therefore we under- 
stand value to mean the potential of 
a study to improve health, broadly 
construed as biological, psychologi- 
cal, or social well-being.16 Studies 
that promise to improve individuals7 
biopsychosocial well-being have 
"health value." 
Health value can be categorized 
along two dimensions: immediate 
versus future health value, and the 
population that receives this value. 
Immediate vs. Future Health 
Value 
Astudy has immediate health value if experts believe that its 
results can be immediately applied 
to improve health and well-being. 
Other studies may produce knowl- 
edge that advances understanding of 
health or illness but will not imme- 
diately improve health. These stud- 
ies have future health value. 
Examples of studies that offer 
immediate value span the spectrum 
of clinical and nonclinical research. 
Some of the most obvious are phase 
I11 trials of new medications. If a 
phase I11 trial finds that the investi- 
gational drug under study is effec- 
tive, it has the potential to improve 
the health of patients as soon as the 
drug receives regulatory approval. 
But other nonclinical studies offer 
immediate value as well. For 
instance, a study of needle-sharing 
practices among intravenous drug 
users might produce results that 
could be translated immediately into 
more effective educational interven- 
tions to promote safer behavior. 
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Similarly, epidemiologic studies that 
define the prevalence of child abuse 
in a population could be used to 
promote legislation or social service 
interventions. 
Examples of studies that offer 
future health value are numerous as 
well. One of the most widely dis- 
cussed and debated is the phase I 
trial, which is a preliminary test of a 
~otent ia ltherapy's safety. Even if a 
~otent ia l  therapy is demonstrated to 
be safe in a phase I trial, its effec- 
tiveness has not yet been demon- 
strated. The results of a phase I trial 
cannot be applied immediately to 
improve health and well-being. 
Other research that offers future 
value includes studies of normal psy- 
chological function, ethnographic 
studies of social interaction, or stud- 
ies of normal physiological function. 
In general, the results of these sorts 
of studies may advance understand- 
ing and they may lead to future 
studies that improve health and 
well-being. However, they are 
unlikely to produce results that 
could directly improve health and 
well-being. Their value lies in their 
contribution to future research. 
The distinction between immedi- 
ate and future value is ethically 
important because, in general, a 
study that offers immediate value 
offers far greater certainty of an 
effect on health and well-being. If 
value is an ethical requirement of 
research, then the threshhold of 
immediate (vs. future) value seems 
logical. For instance, further testing 
that is necessary after a phase I trial 
(e.g. phase I1 and phase 111 trials) 
introduces uncertainty as to whether 
an intervention that is tested in a 
phase I trial will ever be applied in a 
clinical setting to improve health. 
Similarly, the scientific threads that 
connect studies of normal physiolo- 
gy with future studies that offer 
health value are usually difficult to 
discern. Of course, even with a 
phase 111 trial that promises immedi- 
ate health value, there is uncertainty 
whether the intervention will be 
effective, and whether the agent will 
be approved and clinically available. 
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Nevertheless, there is far greater cer- 
tainty that a phase 111 study will 
produce an improvement in health 
or well-being than there is for virtu- 
ally all phase I studies. 
This distinction between immedi- 
ate and future value is based on a 
judgment about whether a study's 
results will improve health or well- 
being. It does not include a judg- 
ment about the magnitude of those 
improvements, the number of 
patients who might benefit from 
them, or the amount of time that it 
will take to complete the study. 
Thus a study that takes several years 
to complete has immediate value if 
its results will produce even a minor 
improvement in the health of a few 
patients. But if another study's 
results cannot immediately improve 
health, it would have only future 
value, even if its results will pave the 
way for future improvements for 
large numbers of persons. 
Two caveats are essential here. 
First, it is important to note that 
these determinations of value should 
be made a priori, during a study's 
design and IRB review. For instance, 
an IRB could conclude that a phase 
111 study of a new medication has 
immediate value. This assessment is 
still valid even if, at the study's con- 
clusion, the newer medication is 
found to be less effective than stan- 
dard care. Indeed, when a study is 
designed to test the equivalency of 
two or more therapies that are cur- 
rently in clinical use, a negative 
result might offer considerable 
immediate value, if one of the thera- 
pies offers substantial advantages in 
terms of its side effect profile, con- 
venience, or cost. 
Second, these assessments are 
probabilistic. That is, they are made 
under conditions of uncertainty and 
must rely on the best information 
available. For a study to have imme- 
diate value, experts need to agree 
that there is a reasonable possibility 
of producing results that would 
improve health and well-being. 
Health Value for Croups of 
Individuals 
7-o see how health value can be assessed in a way that is sensi- 
tive to concerns about justice, it is 
necessary to consider how a study 
may offer value to different groups 
of patients. There are three groups 
for whom IRBs should assess health 
value: future patients, the popula- 
tion from which the research sub- 
jects are selected, and the subjects 
themselves. (Table.) 
Health Value for Future 
Patients.The broadest group for 
whom value can be assessed is that 
of unidentified future patients, to 
whom we implicitly refer when we 
use the common phrase "benefits to 
society." If a study is to offer value 
to future patients, its results must be 
generalizable. This means that the 
sample of subjects in the study must 
be representative. And the study 
must be designed to  answer a ques- 
tion about which there is genuine 
uncertainty. 
A randomized controlled trial to 
determine whether an intervention is 
effective in treating a condition 
might offer immediate value to 
future patients, as might a study to 
evaluate a new diagnostic test. 
Studies to define the prevalence of a 
public health threat or a threat to 
quality of life, such as job-related 
stress, would meet this criterion as 
well if their results could be translat- 
ed into programs or policies to pro- 
mote timely detection and interven- 
tion. 
Studies that offer future value to 
future patients are those that may 
lead to subsequent studies whose 
knowledge will improve the health 
of others. A wide variety of studies 
offer this category of value. For 
instance, studies to define mecha- 
nisms of cell physiology do not pro- 
duce results that will immediately 
improve health, but may lead to 
other research that would. The same 
is true of studies of normal cardio- 
vascular physiology, descriptive 
studies to identify potential bio- 
markers of a disease, and phase I tri- 
als of new medications. 
Health Value for the Subject 
Population. An IRB could also 
determine whether the study is like- 
ly to produce either immediate or 
future health value for a second 
group: the population from which 
the study participants are selected. 
The answer to this question is 
important because it is sensitive to 
concerns about justice in research 
design and recruitment. Specifically, 
this question assesses the concor- 
dance between those who are likely 
to be recruited into a study and 
those who stand to benefit from a 
study's results. 
If a study is to offer immediate 
health value for the target popula- 
tion, several conditions need to be 
met. First, members of that popula- 
tion must have access to any 
improvements in health or health 
care that the study p r o d ~ c e s . ' ~ ~ ' ~  
This requires that a health care 
delivery system exist to provide 
patients affordable access to a treat- 
ment or test. Moreover, the 
providers in that health care system 
must be able to learn of the research 
results and must be able and willing 
to apply them in clinical care. For 
nonclinical research, such as a study 
to assess the prevalence of elder 
abuse among emergency room vis- 
its, this requires a plan to translate 
results into case-finding procedures, 
policy, or services. 
A study that cannot meet these 
requirements would provide only 
future health value to the study pop- 
ulation. One example might be a 
clinical trial of an HIV therapy in 
underdeveloped countries where 
that therapy is not currently avail- 
able. Another would be a study that 
is conducted in a population whose 
members would not have access to a 
new medication that proves to be 
effective because of cost or a restric- 
tive formulary system. 
Some studies offer neither imme- 
diate nor future health value to the 
population from which subjects are 
drawn. In general, these are studies 
that ask a question that is not rele- 
vant to that population, although it 
may be relevant to future patients 
not in the population. One example 
is a study that involves terminally ill 
cancer patients to test a new med- 
ication, like an HIV vaccine, that is 
not related to end-of-life care. 
Another example is a phase I trial 
that involves healthy subjects who 
do not have the disease that the 
study agent is targeted to treat. 
These studies offer neither immedi- 
ate nor potential future clinical 
value for the population of subjects 
who are involved. 
Health Value for Research 
Subjects. Finally, a study's value can 
also be assessed for the subjects 
themselves. Like assessments of 
value to the study population, this 
measure, is sensitive to concerns 
about justice. If subjects take risks 
and assume burdens of research in 
order to produce knowledge about 
a disease, test, or treatment, those 
subjects have a stronger claim than 
other patients on any future 
improvements to health and well- 
being that may result. Benefits from 
the results of a study are distinct 
from other potential benefits, such 
as improved health or decreased 
symptoms, which may accrue to 
subjects over the course of a study. 
Subjects may benefit from a study's 
results but not from their participa- 
tion in the study, or vice versa. 
Benefit from the results of a study is 
also distinct from other indirect or 
"collateral," benefits of participat- 
ing in research.'g For instance, sub- 
jects in a study may benefit if tests 
reveal an undiagnosed medical con- 
dition. However, these subjects will 
not necessarily benefit from the 
aggregate results of the study, which 
define a study's value. 
Three conditions must be met if a 
study is to offer immediate health 
value for its subjects. First, the dis- 
ease or condition under study must 
be chronic or relapsing. This makes 
it possible that the knowledge gen- 
erated by the study will be relevant 
to the subject's care when the study 
is completed. For example, the 
knowledge generated by a study of 
hypertension or sleep apnea is likely 
to benefit the subjects themselves 
because knowledge related to their 
disorder will be relevant to their on 
going care. On the other hand, the 
knowledge generated by a study of 
resuscitation for trauma patients 
would benefit the subjects only in 
the unlikely event that they suffer 
similar trauma again--even if such a 
study offered subjects potential 
direct medical benefits due to the 
research intervention, it would not 
offer immediate health value, 
because they would be unlikely to 
benefit from the knowledge to be 
gained. 
Second, the subjects enrolled 
must live long enough to benefit 
from the knowledge produced. 
Subjects in a trial comparing two 
anti-hypertensive agents are likely to 
benefit from the study's results, 
whereas cancer patients who enroll 
in phase I trials of chemotherapy 
agents are unlikely to benefit from 
knowledge about the efficacy of 
those agents. They are unlikely to 
survive long enough to participate 
in future studies, or to receive the 
agent as part of clinical care. 
However, other phase I trials may 
offer future health value to partici- 
pants-for example, a phase I trial 
of gene therapy for genetic disorders 
that may produce effective therapies 
in the future. If such a study were to 
enroll subjects with a mild form of 
the disorder, who have a favorable 
prognosis, they themselves might 
benefit from future therapies that 
resulted. 
Third, if a study is to offer imme- 
diate or future value for subjects, 
there must be mechanisms in place 
to translate clinically relevant 
knowledge into improved care. This 
means that the results of a study 
must be shared with the subjects or 
their healthcare providers. This 
might involve a letter or telephone 
contact to the subjects, or to each 
subject's physician, outlining the 
study's results for clinical practice. 
Clinical research centers devoted to 
diseases such as cancer, asthma, or 
Alzheimer's disease have an infra- 
structure that is ideally suited to 
achieve this requirement by provid- 
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ing rapid feedback to cli-
nicians, and active edu- Table 
cation programs for Features that Enhance a Study's Value 
patients and families. 
Subjects must also Value for 
have access to therapies Future Patients
that prove to be benefi-
cial. if a medication has 
been approved for clini-
cal use, subjects must 
have access to it through 
their pharmacies and 
health plans, which fur-
ther means they must 
have the health insur-
ance or resources neces-
sary to obtain it. A 
study of a medication 
that has not been 
Results are generalizable 
Study has clinically realistic 
inclusion criteria 
Research question(s) are 
relevant t o  health and well-
being 
approved for clinical use 
would have immediate clinical value 
only if subjects have access to the 
medication through an open label 
phase. That is, if a medication has 
not yet been approved, the only way 
in which research subjects stand to 
benefit from the study's results 
immediately is if the medication is 
made available through an open 
label continuation trial. 
Balancing Risks, Potential Benefits 
& Value 
2'-'his analysis is useful only if it 
h e l p s  IRBs to determine whether 
a study's risks are balanced by its 
benefits and by the importance of 
the knowledge to be gained as feder-
al regulations require (45 CFR 46.111 
(a)(z)).Specifically, an IRB must con-
sider whether a study's risks are rea-
sonable in relation to its benefits, 
and whether any risks without corre-
sponding benefits are reasonable in 
proportion to the knowledge to be 
gained (45 CFR 46.1 11 (a)(2)).It is in 
the second analysis that IRBs might 
use the categories described above. 
This analysis requires the IRB to 
focus on the components of the 
study that are designed solely to 
answer a research question. 
It is important to note, though, 
that IRBs need not use these cate-
gories for guidance in reviewing all 
studies. For instance, considerations 
Value for the Study Value for Research 
Population Subjects 
Current or planned mecha-
nisms exist t o  translate results 
into improvements in 
care/policy 
An intervention that proves 
t o  be effective will be avail-
able to  the population 
Research question(s) are 
relevant t o  the population 
of value are not necessary when all 
of a study's risks are outweighed by 
its potential benefits to subjects 
themselves. If no additional risks or 
burdens are imposed in order to 
gather generalizable data, an IRB 
need not consider the study's risk-
value balance. Similarly, when a 
study offers no potential benefits, 
but also poses only minimal risks 
(e.g., an anonymous survey, or most 
ethnographic research) value need 
not be considered; a requirement of 
validity is sufficient. 
There are three categories of stud-
ies, however, for which value should 
be assessed. First, IRBs should assess 
a study's value for the subject popu-
lation if it recruits from a vulnerable 
or captive population, i.e., those 
who are "relatively (or absolutely) 
incapable of protecting their own 
interests."'" These populations might 
include adults with cognitive impair-
ment, residents in chronic care facili-
ties, patients in intensive care units, 
and underserved populations both in 
this country and abroad. These pop-
ulations are particularly susceptible 
to opportunistic recruiting that takes 
advantage of limited knowledge or a 
paucity of alternatives to research 
participation. To offset this risk, and 
to discourage opportunistic recruit-
ing, IRBs should consider the value 
that a study promises to the popula-
tion from which subjects are select-
* Study focuses on 
chronic/relapsing condition 
Subjects have adequate life 
expectancy t o  benefit 
Investigators have described 
mechanisms o f  follow-up and 
continued contact with sub-
jects 
ed. This requirement is an extension 
of the Common Rule's regulations 
governing research that involves pris-
oners, which requires that research 
involving these vulnerable subjects 
be designed to advance knowledge 
about conditions that are relevant to 
that population (45 CFR 46.306). 
If a study recruits vulnerable 
patients, and offers immediate health 
value to future patients, it should 
also offer immediate health value to 
the population from which the study 
subjects are selected. This require-
ment should be applied to most clini-
cal trials. For instance, a study of 
two anti-hypertensive medications 
that offers immediate health value 
for future patients, and recruits sub-
jects from a disadvantaged inner-city 
population, should offer the same 
value to the study population. This 
means that the study's results must 
be applicable to the population. 
More importantly, there should be 
adequate systems of health care 
delivery and adequate access to care 
to ensure that the results of that 
research reach that population. 
Similarly, if pharmaceutical trials 
that offer immediate value in the 
developed world are conducted in 
underdeveloped countries, they 
should offer immediate value to 
patients in those countries as well. 
The second class of studies for 
which this taxonomy is useful are 
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those in which the study's risks are 
significant, there are no potential 
benefits to subjects, and the subjects 
themselves are unable to give 
informed consent, such as a wash- 
out study that involves patients with 
active schizophrenia. This study 
may pose substantial risks to the 
subjects but offers little or no direct 
medical benefit if subjects would be 
responsive to standard the rap^.^' 
The substantial ethical concern 
posed because the subjects them- 
selves do not stand to benefit direct- 
ly from research participation in 
such cases are magnified by chal- 
lenges of informed consent. 
These concerns may be amelio- 
rated if a study's results will have 
immediate health value for the sub- 
jects themselves. Direct benefits 
from the knowledge to be gained 
are distinct from benefits derived 
during the study as we have seen, 
but can nevertheless offset some of 
the risks of study participation. 
IRBs should thus determine whether 
such high risk studies are likely to 
offer immediate health value for the 
subjects themselves. For instance, if 
a wash-out study could determine 
whether a medication is effective, 
investigators should be prepared not 
only to describe how the results of 
the trial will be relayed to the sub- 
jects or their clinicians, they should 
also be able to outline plans for 
ensuring access to this new therapy. 
A third class of studies for which 
this taxonomy of value is useful are 
studies that present greater than 
minimal risks but offer no prospect 
of direct benefit, such as phase I tri-
als. For these studies, at least for 
patient-subjects, altruism should 
arguably be the most important rea- 
son that subjects enroll. IRBs and 
investigators have an important 
opportunity to take this altruism 
seriously by incorporating a descrip- 
tion of value into the informed con- 
sent process and the informed con- 
sent document itself. Ideally, the 
informed consent process for these 
trials should include a description of 
the value that the study will offer 
using the categories outlined above, 
in language that is easily under- 
standable. This disclosure can help a 
potential subject to determine 
whether the research risks are rea- 
sonable in proportion to his or her 
desire to help others. 
Moving Debate Forward 
e describe a taxonomy of Wvalue that should be useful to 
investigators and particularly to 
IRBs in assessing the ethics of pro- 
posed research. This taxonomy 
relies on the concepts of immediate 
and future health value and consid- 
ers the persons who are likely to 
benefit from the knowledge to be 
gained. Together, these concepts 
provide necessary structure to the 
assessment of the importance of the 
knowledge to be gained from the 
research. 
It should be noted, however, that 
this taxonomy should be open to 
discussion. Like categories of risk, 
benefit, and informed consent, cate- 
gories of value must be further 
refined through deliberation among 
investigators, IRBs and the public. 
For instance, to refine categories of 
value, it will be important to under- 
stand the way that subjects and 
their families understand value. In 
addition, discussion is needed to 
determine how investigators and 
IRBs can efficiently and fairly apply 
a taxonomy of value. 
H David Casarett, MD, is on the faculty of 
the VA Center for Health Equity Research 
and Promotion and assistant professor of 
geriatric medicine at the University of 
Pennsylvania; Jason H.T. Karlawish, MD, is 
assistant professor of geriatric medicine at the 
University of Pennsylvania, Philadelphia; and 
Jonathan D. Moreno, PhD, is Kornfeld 
Professor and director of the Center for 
Biomedical Ethics at the University of 
Virginia in Charlottesville, Virginia. 
References 
1.World Medical Association, 
Declaration of Helsinki. Reprinted in: B. 
Brody, The Ethics of Biomedical Research. 
An International Perspective. New York: 
Oxford University Press, 1998. Also available 
at http://www.wma.ner/e/policy/i7-c-e.html. 
2. The Nuremberg Code. Reprinted in: 

Brody, B. The Ethics of Biomedical Research. 

An International Perspective. New York: 

Oxford University Press, 1998: 213. 
3. Freedman B. Placebo-controlled trials 
and the logic of clinical purpose. IRB 1990; 
12(6): 1-6. 
4. Advisory Committee on Human 
Radiation Experiments. Final Report. 
Washington, D.C.: Government Printing 
Office, 1995. 
5 .  Emanuel EJ, Wendler D, Grady C. 
What makes clinical research ethical? JAMA 
2000; 283: 2701-11. 
6. Capron AM. Ethical and human-rights 
issues in research on mental disorders that 
may affect decision-making capacity. NEJM. 
1999; 340: 143-34. 
7. Karlawish JHT. Clinical value: The 
neglected axis in the system of research 
ethics. Accountability in Research 1999; 7: 
255-64. 
8. Michels R. Are research ethics bad for 
our mental health? NEJM. 1999; 340: 
1427-30. 
9. National Bioethics Advisory 
Commission. Ethical and Policy Issues in 
Research Involving Human Participants. 
Bethesda, Md.: NBAC, 2001: Recommend-
ation 4.1. 
lo. Freedman B. Scientific value and 
validity as ethical requirements for research: 
A proposed explication. IRB 1987; 9(6 ): 
7-10. 
11.Rutstein DR. The ethical design of 
human experiments. In: Freund PA, ed. 
Experimentation with Human Subjects. New 
York: George Braziller 1970: 383-401. 
12. National Commission for the 
Protection of Human Subjects of Biomedical 
and Behavioral Research. The Belmont 
Report: Ethical Principles and Guidelines for 
the Protection of Human Subjects of 
Research. Washington D.C.: U.S. 
Government Printing Office 1979: 5. 
13. See ref. 5 ,  Emanuel et al. 2000. 
14. See ref. 2, Brody 1998: 213. 
15. See ref. 1, World Medical Association 
2000. 
16. Engel GL. The need for a new med- 
ical model: A challenge for biomedicine. 
Science 1977; 196: 129-36. 
17. Grady C. Science in the service of 
healing. Hustings Center Report 1998; 28(6): 
34-38. 
18. Glantz LH, Annas GJ, Grodin MA, et 
al. Research in developing countries. 
Hustings Center Report 1998; z8(6): 38-42. 
19. King, NMP. Defining and describing 

benefit appropriately in clinical trials. Journal 

of Law, Medicine e9 Ethics 28: 332-343 

(2001). 
zo. Levine RJ. Ethics and Regulation of 
Clinical Research, zd ed. Baltimore: Urban 
and Schwartzenberg, 1986: 7. 
21. Carpenter WT, Schooler NR, Kade 
JM. The rationale and ethics of medication- 
free research in schizophrenia. Archives of 
Genetic Psychology 1997; 54 : 401-7. 
I R B :  E T H I C S  & HUMANRESEARCH 
